Neutralizing Antibody Conversion With OnabotulinumtoxinA From Global Studies Across Multiple Indications With A Focus On Movement Disorders: A Meta-Analysis
Objective: A meta-analysis of clinical trial data across 10 indications for onabotulinumtoxinA was performed to assess incidence of neutralizing antibody (nAb) formation with a focus…Disparities in Access to Spasticity Chemodenervation Specialists in the United States: a National Analysis of Medicare Data
Objective: To explore the variations in access to spasticity chemodenervation specialists across several geographical, ethnic, racial, and population density factors. Background: Equity in access to…OnabotulinumtoxinA treatment in patients with upper limb and lower limb spasticity from the ASPIRE study
Objective: Examine onabotulinumtoxinA utilization in patients with upper limb (UL) and lower limb (LL) spasticity from the Adult Spasticity International Registry (ASPIRE) study to gain…Assessing effectiveness of abobotulinumtoxinA injections for adult lower limb spasticity in routine clinical practice: The ongoing AboLiSh study
Objective: The aim of this ongoing observational study is to systematically assess goal attainment over 16 months in patients treated with ≥1 abobotulinumtoxinA (aboBoNT-A) injection(s)…Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Lower Limb Spasticity in Japanese Subjects
Objective: To confirm the efficacy and safety of incobotulinumtoxinA (INCO; Xeomin®, Merz Pharmaceuticals GmbH) in East Asian subjects from study sites in Japan with post-stroke…Pregnancy Outcomes Following Exposure to OnabotulinumtoxinA Update – 29 Years of Safety Observation
Objective: The present study evaluated pregnancy outcomes following onabotulinumtoxinA exposure to provide a cumulative 29-year safety update. Background: A previous publication of pregnancy outcomes in…Management of Cervical Dystonia & Spastic Paresis with Botulinum Neurotoxin-A: results from the INPUT survey
Objective: To describe current practices among physicians using botulinum toxin-A (BoNT-A) to treat spastic paresis (SP) and cervical dystonia (CD). Background: BoNT-A is an effective…Multi-level and multi-pattern lower- and upper-limb spasticity treatment with incobotulinumtoxinA in children and adolescents with cerebral palsy
Objective: Assess efficacy and safety of incobotulinumtoxinA in lower-limb (LL) or combined LL/upper-limb (LL/UL) spasticity in children and adolescents with cerebral palsy (CP). Background: Ambulant…Phenotyping spasticity-associated tonic spasms: implications for therapy
Objective: To evaluate common phenotypes of tonic spasms (TS) in patients with spasticity and inform therapeutic interventions. Background: Spasticity can be associated with several hyperkinetic…Treatment with Botulinum Toxin for Refractory Fever caused by Severe Spasticity
Objective: Present a series of cases of patients with refractory fever associated to spasticity secondary to a brain or spinal cord injury who developed refractory…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.